Wegovy Flex pen: what it is and how it differs from FlexTouch

What exactly is the Wegovy Flex pen, and why does the name cause confusion?

Novo Nordisk produces Wegovy in a family of pre-filled injection pens, and 'Flex' refers to the pen platform rather than a separate product. The Wegovy FlexTouch is the version most commonly discussed in UK dispensing contexts: a pre-set, single-dose pen with an auto-injection mechanism, a covered needle that never needs to be seen or handled separately, and a lock that activates once the dose has been delivered. You press, hold, and the device does the rest.

The confusion is understandable. Medical device naming conventions are not designed with patients in mind, and searching for 'Wegovy Flex' returns a mixture of results covering the full pen range. The practical difference between variants is mainly ergonomic, the mechanism of delivery rather than the medicine or its licensed effect. The semaglutide inside is identical across pen formats.

If you are already on Wegovy and uncertain which pen you have been prescribed, the information leaflet inside the box and your prescriber are the definitive sources. Changing pen format, or moving between doses, is always a prescriber decision, not something to manage independently based on packaging comparisons. You can read more about how the pen format relates to the wider treatment on our Wegovy FlexTouch overview.

Does the pen format affect how well semaglutide works?

The device does not alter the medicine's pharmacology. What the FlexTouch and its Flex-family siblings deliver is the same semaglutide molecule at the same dose. Clinical trial evidence for Wegovy's effectiveness was built using the licensed semaglutide doses, not around any particular pen design.

In the STEP 1 trial, published in the New England Journal of Medicine, adults treated with semaglutide 2.4 mg achieved an average body-weight reduction of around 15% over 68 weeks, alongside lifestyle support. Results vary between individuals, and clinical trials involve structured conditions that differ from everyday life, 15% is the average, not a guarantee. A newer higher-dose pen (7.2 mg) was approved by the MHRA in April 2026, with trial data suggesting around 20.7% average weight loss over 72 weeks at that dose.

Pen comfort, confidence with injection technique, and consistent weekly timing matter for adherence, and adherence matters for results. In that sense, a pen that feels manageable to use is genuinely part of the picture. Our guide on managing injection-related responses covers practical technique tips that apply regardless of which pen format your prescriber selects.

Who can be prescribed Wegovy in the UK, and through what routes?

Wegovy holds a UK licence for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Having a qualifying BMI does not guarantee a prescription; a prescriber reviews the full picture, including medical history, current medicines, and any contraindications.

On the NHS, NICE recommends Wegovy for use within specialist weight management services, for a maximum of two years, for adults with a BMI of 35 or above and at least one comorbidity. The NICE technology appraisal TA875 sets out these criteria in full. Waiting lists for specialist services can be long, and not everyone meets the NHS thresholds.

Private prescription routes (through a regulated online pharmacy like nume) are available to people who meet the licensed eligibility criteria but are not waiting for NHS referral. Our semaglutide overview explains how the private assessment process works and what clinical checks are involved. For a broader look at weight-loss treatment options, our treatment overview sets out the landscape plainly.

Are there safety considerations specific to the Flex pen or to Wegovy more broadly?

The pen device itself carries standard sharps considerations: used pens should be disposed of in an approved sharps container and never placed in household recycling or general waste. Beyond that, the safety profile of Wegovy relates to semaglutide rather than the delivery device.

The most common side effects are gastrointestinal: nausea tends to be the one people notice most, particularly in the first weeks or after a dose increase. Vomiting, constipation, diarrhoea, and indigestion are also reported, and most people find these settle as their body adjusts. Severe, persistent stomach pain that extends towards the back warrants prompt medical attention, this can be a sign of acute pancreatitis, which the MHRA has highlighted as an infrequent but serious risk with GLP-1 medicines.

Wegovy is not suitable during pregnancy, while breastfeeding, or when trying to conceive. It is not licensed for anyone under 18. The NHS semaglutide patient page covers the full side-effect profile and when to seek medical help, and you can also find dosing and presentation details on our Wegovy 1 page. Any suspected side effects can be reported through the MHRA's Yellow Card scheme.

If you have questions about whether Wegovy is right for you, or want to understand what the consultation involves, you can start a free consultation with our prescribers, who review every application personally on the same day it is submitted.